Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, NewTrader2017
Search This Board: 
Last Post: 11/17/2017 4:16:44 PM - Followers: 122 - Board type: Free - Posts Today: 18
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Quarterly Report (10-q) 11/14/2017 04:41:42 PM
INNV News: Current Report Filing (8-k) 11/14/2017 04:24:20 PM
INNV News: Current Report Filing (8-k) 11/14/2017 06:13:49 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:57:33 PM
INNV News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 04:56:09 PM
#11803  Sticky Note $19B market. I think I'd be loading up BooDog 10/03/17 06:04:18 AM
#11037  Sticky Note Innovus Pharma Orders its First Commercial Batch of kkpennies 08/09/17 02:44:19 PM
#12362   In fact ShawnP, Apricus soared to over $56 rebelwithacause 11/17/17 04:08:02 PM
#12361   What did he do? RS? jtaylor68 11/17/17 03:49:37 PM
#12358   It's like deja vu all over again. Yevvy, twistedfreak 11/17/17 02:58:50 PM
#12357   Dr. Damaj very Optimistic person ..... I do healthywelth 11/17/17 02:35:14 PM
#12356   Don's forget Dr. Da did it with Apricus ShawnP123 11/17/17 02:27:16 PM
#12355   Healthywelth, first Dr.Damaj claimed that INNV could be gi197845 11/17/17 02:13:32 PM
#12354   Depends on when we surpass $0.15. If after jtaylor68 11/17/17 01:48:05 PM
#12353   do u think this will move up this NewTrader2017 11/17/17 12:52:00 PM
#12352   add more and wait till next earning. Thanks for news mike007 11/17/17 10:23:24 AM
#12351   Nice. 2018 showing the potential. $INNV BooDog 11/17/17 10:08:40 AM
#12350   Lots of stock on the offer. Same ol ShawnP123 11/17/17 10:04:50 AM
#12349   See ThruEquity Issues Update on Innovus Pharmaceuticals (INNV) mike007 11/17/17 09:03:16 AM
#12348   jtaylor- by near to midterm, I'm assuming you ShawnP123 11/17/17 08:17:59 AM
#12346   fried and seasoned perhaps TrueTrades 11/16/17 10:15:29 PM
#12345   Seasoned long investors don't only care about the jtaylor68 11/16/17 09:14:20 PM
#12344   His wife holds another 4M. So together around 24M. jtaylor68 11/16/17 08:45:17 PM
#12341   It's called intelligent debate. Sorry I'm violating your jtaylor68 11/16/17 08:30:10 PM
#12339   Around 20M. 13,5M awarded, 6,5M bought. jtaylor68 11/16/17 07:41:45 PM
#12338   How many shares Mr Damaj holds?? How much NewTrader2017 11/16/17 07:23:22 PM
#12337   TF, first of all back to my initial jtaylor68 11/16/17 07:17:26 PM
#12336   how dare you! TrueTrades 11/16/17 05:44:28 PM
#12332   But Dr. D has been saying all year twistedfreak 11/16/17 04:46:48 PM
#12331   Nice Reminder - We will be rewarded if healthywelth 11/16/17 04:18:46 PM
#12330   They have to trim their overall expenses by twistedfreak 11/16/17 04:15:06 PM
#12328   No need to will go up once healthywelth 11/16/17 03:42:36 PM
#12327   Those who don't realize the value of this jtaylor68 11/16/17 03:09:32 PM
#12326   Listen, they brought in $2.2M in revs and twistedfreak 11/16/17 03:08:24 PM
#12324   youll get over it TrueTrades 11/16/17 02:45:42 PM
#12323   I'm sorry to hear you often pick stocks jtaylor68 11/16/17 02:36:00 PM
#12322   i hold a little worthless rxmd scamaramma TrueTrades 11/16/17 02:26:48 PM
#12321   Same goes for you. Speaks volumes if you jtaylor68 11/16/17 02:22:16 PM
#12320   If you can't acknowledge natural disasters as legitimate jtaylor68 11/16/17 02:19:29 PM
#12319   Are you seriously claiming that they only have jtaylor68 11/16/17 02:15:54 PM
#12317   honey used to make excuses for the co too TrueTrades 11/16/17 02:07:36 PM
#12316   FYI, I ordered a Fluticare 2pack from Amazon gi197845 11/16/17 01:45:46 PM
#12315   NewTrader2017, I'm sorry you got stuck holding this gi197845 11/16/17 01:44:33 PM
#12314   So why do 4 men in an office twistedfreak 11/16/17 01:40:54 PM
#12313   I have a bid in at 8 cents biotech2 11/16/17 01:38:14 PM
#12312   Insane cash burn? Lol. jtaylor68 11/16/17 12:50:24 PM
#12311   yes, that's why Im not putting in more biotech2 11/16/17 12:05:13 PM
#12310   will be drifting down from here at .09 twistedfreak 11/16/17 11:58:18 AM
#12309   u r going to hold for another year? NewTrader2017 11/16/17 11:44:29 AM
#12308   my average is 11 cents as well. Got biotech2 11/16/17 11:42:09 AM
#12307   i accept i was wrong, where do u NewTrader2017 11/16/17 11:34:41 AM
#12306   should have heeded my advice and I should twistedfreak 11/16/17 11:31:00 AM
#12305   are we going back to 8 , I NewTrader2017 11/16/17 11:16:14 AM
#12304   The counterfeit issue has brought orders to a jtaylor68 11/16/17 09:51:46 AM
#12303   Let's see how the rest of the week ShawnP123 11/16/17 09:43:55 AM
#12302   No, put your dictionary down. jtaylor68 11/16/17 09:17:17 AM
#12301   No, put your dictionary down. It was a twistedfreak 11/16/17 09:04:03 AM